Form 4: Labcorp Executive's RSU Vesting and Tax Withholding

Labcorp Holdings Inc. EVP Brian J. Caveney reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Brian J. Caveney, EVP, President of ED, CMO & CSO of Labcorp Holdings Inc., reported transactions involving common stock and restricted stock units.
• On February 11, 2026, 740 restricted stock units (RSUs) vested, converting into 740 shares of common stock.
• These vested RSUs were part of a grant that vests in three equal annual installments, with the first installment beginning on February 11, 2026.
• Concurrently, 211 shares of common stock were disposed of at a price of $289.89 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Caveney beneficially owns 31,606.9234 shares of common stock directly.
• Caveney also holds an aggregate of 4,170 restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting standard executive compensation activities without indicating any significant positive or negative operational or financial developments for the company.

Positives

• The vesting of 740 restricted stock units indicates continued equity compensation for a key executive, aligning management interests with shareholder value.
• The executive's overall beneficial ownership of common stock remains substantial at 31,606.9234 shares, demonstrating continued significant stake in the company.

Negatives

• A portion of the vested shares (211 shares) was sold to cover tax withholding obligations, which is a standard practice and not indicative of a negative outlook.

Future Outlook

The filing indicates future vesting events for the remaining restricted stock units, as the grant vests in three equal annual installments beginning on February 11, 2026.

Industry Context

StockSavvy.ai notes that routine insider transactions like RSU vesting and tax-related sales are common across industries, reflecting standard executive compensation practices rather than specific industry trends or competitive positioning.

Comparison to Industry Standards

• StockSavvy.ai observes that the practice of granting restricted stock units and subsequent share sales for tax withholding is a standard component of executive compensation packages across publicly traded companies, particularly in the healthcare and diagnostics sector.
• This aligns with common practices seen in companies like Quest Diagnostics (DGX) or other large healthcare providers, where equity incentives are used to align executive interests with long-term shareholder value.
• The specific volume of shares and the sale price are consistent with typical compensation structures for executives at this level within a large-cap company.

Stakeholder Impact

• Shareholders: The vesting of RSUs aligns executive incentives with shareholder interests, while the tax-related sale is a routine event with minimal direct impact on overall share value.
• Employees: No direct impact on general employees.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Future annual installments of the restricted stock unit grant are expected to vest, continuing from February 11, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax withholding). It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for buying or selling.

Keywords

Labcorp Holdings Inc., LH, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Withholding, Executive Compensation, Brian J. Caveney